Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
Business Wire•23/09/2026•16:01 ET
0
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
–Mr. Cumbo brings deep experience commercializing new medicines for people with rare genetic diseases–
Get started
Create a free account to read the full story and Whiz Insights.